Merck Announces Third-Quarter 2015 Financial Results
Dateline City:
KENILWORTH, N.J.
Increased Non-GAAP EPS by 7 Percent to $0.96; GAAP EPS of $0.64
Raised 2015 Full-Year Non-GAAP EPS Target to a Range of $3.55 – $3.60 and GAAP EPS Target to a Range of $1.64 – $1.74
Worldwide Sales Were $10.1 Billion, a Decrease of 5 Percent; Excluding the Impact of Foreign Exchange, Acquisitions and Divestitures, Worldwide Sales Grew 4 Percent
Advanced KEYTRUDA Program
FDA Approved sBLA for the Treatment of Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
In KEYNOTE-010 Study KEYTRUDA Showed Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced NSCLC Whose Tumors Express PD-L1
Third-Quarter Sales Were Approximately $160 million
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced financial results for the third quarter of 2015.
Language:
English
Contact:
MerckMedia:Lainie Keller, 908-236-5036Steven Cragl...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals | Study